The study, led by Sun and colleagues, looked at 546 blood samples from 160 patients with high-risk stage II/III HER2-negative breast cancer getting neoadjuvant treatment, meaning therapy before surgery. Some received chemotherapy alone, while others got chemotherapy plus immunotherapy. The team ran RNA sequencing on peripheral blood and asked a deceptively simple question: can the immune chatter in blood tell us something useful about the tumor and the odds of treatment success? (Sun et al., 2026)
Short answer: yes, and in a way that feels more practical than a lot of precision-oncology promises that arrive wearing a tuxedo and leave wearing a shrug.
Patients with triple-negative breast cancer, the subtype that lacks ER, PR, and HER2, showed stronger immune activation patterns in blood. That fits the broader story of triple-negative disease: it is often more aggressive, more chaotic, and more likely to interact heavily with the immune system. Triple-negative tumors are basically the loud neighbors on the block - stressful, but at least you know they are home.
The T-cell plot twist
One of the clever bits here involves T-cell receptor diversity and clonality. If that phrase makes your brain try to leave the building, fair. Here is the simple version.
Your T cells carry receptors that act like millions of slightly different lockpicks. High diversity at baseline means you have a broad toolkit. Clonal expansion after treatment means some of those T cells found a real target and started multiplying like they had just discovered free parking in Manhattan.
That is more or less what the authors saw. Among patients getting chemoimmunotherapy, people who responded early tended to start with a more diverse T-cell repertoire, then showed rapid expansion and activation of specific T-cell clones after just one treatment cycle. In puzzle terms, the immune system did not just own a big box of pieces - it started snapping the right ones together early.
That matters because current biomarkers are often annoyingly static. A tumor biopsy gives you one tissue sample from one place at one time. Tumors, meanwhile, love heterogeneity. They are the kind of opponent that changes outfits mid-heist. Reviews over the past two years have kept hammering this point: breast cancer immunity is dynamic, and the systemic immune response outside the tumor may matter more than we once appreciated (Harris et al., 2024; Gerashchenko et al., 2024).
Why this is more than a neat lab trick
The punchline is not just “blood contains information.” We already suspected that. The stronger claim is that the team built a multiparametric blood-based biomarker using baseline and early on-treatment immune features to predict who would benefit from pembrolizumab. Then they validated it in an independent cohort of 59 patients treated with dostarlimab. Different cohort, different PD-1 drug, still useful. That is the sort of detail that makes oncologists sit up straighter.
And the timing matters. Immunotherapy in early triple-negative breast cancer is now a real part of clinical practice, especially after the KEYNOTE-522 results showed meaningful survival benefit with pembrolizumab added to neoadjuvant chemotherapy (Schmid et al., 2024). Meta-analyses have also supported checkpoint inhibitor plus chemotherapy approaches in early breast cancer, with the clearest gains in triple-negative disease (JAMA Oncology, 2024). The field’s headache is no longer “does this ever work?” It is “who actually needs it, who can skip it, and who should switch fast if it is not working?”
That is where a blood test becomes very attractive. Not magic. Just useful. Less invasive than serial biopsies, easier to repeat, and better suited to catching treatment-induced immune changes in real time. Reviews focused on pembrolizumab and liquid biopsy keep circling the same challenge: we need better ways to choose patients, monitor response, and avoid overtreating people who are already doing fine (O'Rourke et al., 2024; Yang et al., 2023).
Of course, there is still a grown-up footnote. This is not ready to replace established clinical decision-making tomorrow morning. Blood-based immune signatures need broader validation, standardization, and proof that using them actually improves patient outcomes. Oncology has seen many “promising biomarkers” vanish into the mist like Victorian airships.
Still, this paper adds a satisfying piece to the bigger picture. It suggests that the immune battle in breast cancer is not trapped inside the tumor. Some of the action spills into blood, where we can watch it without sending a needle on a second mission. And if that holds up, the future may involve fewer invasive biopsies and more treatment decisions based on how the immune system is behaving right now, not how the tumor looked weeks ago.
References
-
Sun X, Ocampo AA, Hanna A, et al. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Science Translational Medicine. 2026. DOI: 10.1126/scitranslmed.aec2358
-
Harris MA, Savas P, Virassamy B, et al. Towards targeting the breast cancer immune microenvironment. Nature Reviews Cancer. 2024;24:554-577. DOI: 10.1038/s41568-024-00714-6
-
Gerashchenko T, Frolova A, Patysheva M, et al. Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity. Advanced Biology. 2024;8(7):e2400140. DOI: 10.1002/adbi.202400140
-
Schmid P, Cortes J, Dent R, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine. 2024;391:1981-1991. DOI: 10.1056/NEJMoa2409932
-
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Oncology. 2024;10(10):1331-1341. DOI: 10.1001/jamaoncol.2024.3456
-
O'Rourke H, Hart C, De Boer RH. Current usage of pembrolizumab in triple negative breast cancer (TNBC). Expert Review of Anticancer Therapy. 2024;24(5):253-261. DOI: 10.1080/14737140.2024.2341729
-
Yang J, Qiu L, Wang X, et al. Liquid biopsy biomarkers to guide immunotherapy in breast cancer. Frontiers in Immunology. 2023;14:1303491. DOI: 10.3389/fimmu.2023.1303491
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.